Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Asset disposition
Revolution Medicines, Inc. (RVMD) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
08/08/2023 8-K Quarterly results
Docs: "Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress Company to provide clinical updates for RMC-6236 at Triple Meeting and ESMO Congress 2023 and initial clinical findings for RMC-6291 at Triple Meeting Planning underway for one or more single agent pivotal trials with RMC-6236 and the first combination study of RMC-6236 and RMC-6291 Announced acquisition of EQRx, Inc. expected to add more than $1 billion in additional capital to balance sheet Webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., August 8, 2023"
08/01/2023 8-K Quarterly results
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/08/2023 8-K Quarterly results
Docs: "Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress First Wave of Investigational RAS Inhibitors – RMC-6236 , RMC-6291 and RMC-9805 – progressing on plan Appointment of chief medical officer and key leaders across late-stage development and commercial planning $909.8 million in cash, cash equivalents and investments at the end of first quarter 2023 Conference call and webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., May 8, 2023"
03/07/2023 8-K Asset disposition
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, among Revolution Medicines, Inc. and J.P. Morgan Securities LLC, Cowen and Company, LLC, SVB Securities LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein",
"Opinion of Latham & Watkins LLP"
02/27/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress Early clinical data on RMC-6236 provided in support of RAS Inhibitor platform validation Additional data releases for RMC-6236 and RMC-6291 expected in 2023 RMC-9805 expected to begin clinical development in mid-2023 Growing pipeline of development-stage assets, including RMC-0708 , that target every major RAS cancer mutation hotspot Webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., February 27, 2023"
01/10/2023 8-K Investor presentation
Docs: "HIGH UNMET NEED IN RAS-ADDICTED CANCERS"
12/07/2022 8-K Quarterly results
11/07/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress"
09/01/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/09/2022 8-K Quarterly results
Docs: "Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress"
07/22/2022 8-K Quarterly results
07/13/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
02/28/2022 8-K Quarterly results
01/11/2022 8-K Investor presentation
Docs: "Company presentation"
11/10/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress"
11/04/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
08/11/2021 8-K Quarterly results
Docs: "Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress"
06/23/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
04/30/2021 8-K Quarterly results
03/08/2021 8-K Quarterly results
03/02/2021 8-K Quarterly results
02/01/2021 8-K Results of Operations and Financial Condition
11/12/2020 8-K Quarterly results
Docs: "Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress"
08/10/2020 8-K Quarterly results
06/22/2020 8-K Investor presentation
Docs: "Company presentation"
06/18/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/14/2020 8-K Quarterly results
04/21/2020 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy